FRED Stock Overview
A health care company, provides products and services for chronically ill patients.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.33 |
| 52 Week High | €31.22 |
| 52 Week Low | €24.01 |
| Beta | 1.04 |
| 11 Month Change | 0.088% |
| 3 Month Change | 14.63% |
| 1 Year Change | 12.67% |
| 33 Year Change | -36.08% |
| 5 Year Change | -40.49% |
| Change since IPO | 9.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRED | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -4.8% | -1.5% | 1.1% |
| 1Y | 12.7% | -25.9% | 8.1% |
Return vs Industry: FRED exceeded the UK Healthcare industry which returned -26.7% over the past year.
Return vs Market: FRED exceeded the UK Market which returned 7.8% over the past year.
Price Volatility
| FRED volatility | |
|---|---|
| FRED Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: FRED has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FRED's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 190,863 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRED fundamental statistics | |
|---|---|
| Market cap | €15.81b |
| Earnings (TTM) | €312.00m |
| Revenue (TTM) | €22.46b |
50.7x
P/E Ratio0.7x
P/S RatioIs FRED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRED income statement (TTM) | |
|---|---|
| Revenue | €22.46b |
| Cost of Revenue | €17.35b |
| Gross Profit | €5.11b |
| Other Expenses | €4.79b |
| Earnings | €312.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 22.74% |
| Net Profit Margin | 1.39% |
| Debt/Equity Ratio | 62.2% |
How did FRED perform over the long term?
See historical performance and comparison